{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:25:06Z","timestamp":1793816706181,"version":"4.6.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jhepr.2026.101835","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:27:42Z","timestamp":1774546062000},"page":"101835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Response-guided bulevirtide \u00b1 pegylated interferon alfa-2a: Long-term outcomes observed in the nationwide Austrian hepatitis D cohort study"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2587-1385","authenticated-orcid":false,"given":"Michael","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5353-5102","authenticated-orcid":false,"given":"Marlene","family":"Hintersteininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7762-7483","authenticated-orcid":false,"given":"Caroline","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Panzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Pfisterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Loschko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3398-6120","authenticated-orcid":false,"given":"Lukas","family":"Hartl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Dorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2337-6695","authenticated-orcid":false,"given":"Hermann","family":"Laferl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert F.","family":"St\u00e4ttermayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Mandorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Graziadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4525-3549","authenticated-orcid":false,"given":"Andreas","family":"Maieron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3598-7848","authenticated-orcid":false,"given":"Alexander","family":"Moschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5508-8271","authenticated-orcid":false,"given":"Vanessa","family":"Stadlbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Madl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan W.","family":"Aberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Zoller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gschwantler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Jachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101835_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(10)61931-9","article-title":"Hepatitis delta virus","volume":"378","author":"Hughes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.101835_bib2","first-page":"113","article-title":"The role of the HBV envelope proteins in the HDV replication cycle","volume":"307","author":"Sureau","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.jhepr.2026.101835_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1056\/NEJMra2212151","article-title":"Hepatitis D virus infection","volume":"389","author":"Asselah","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101835_bib4","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhepr.2026.101835_bib5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jhep.2023.10.043","article-title":"Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories","volume":"80","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101835_bib6","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jhep.2020.06.038","article-title":"Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta","volume":"73","author":"Roulot","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101835_bib7","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1017\/S0950268818001942","article-title":"Hepatitis delta virus and hepatocellular carcinoma: an update","volume":"146","author":"Romeo","year":"2018","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jhepr.2026.101835_bib8","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s12072-023-10575-0","article-title":"Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection","volume":"17","author":"Wranke","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2026.101835_bib9","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/jvh.13577","article-title":"Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: a systematic review and meta-analysis of longitudinal studies","volume":"28","author":"Kamal","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhepr.2026.101835_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2893.2005.00601.x","article-title":"Treatment of hepatitis D","volume":"12","author":"Niro","year":"2005","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhepr.2026.101835_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101835_bib12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101835_bib13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101835_bib14","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s40265-020-01400-1","article-title":"Bulevirtide: first approval","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jhepr.2026.101835_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL Clinical Practice Guidelines on hepatitis delta virus","volume":"79","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101835_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa2314134","article-title":"Bulevirtide combined with pegylated interferon for chronic hepatitis D","volume":"391","author":"Asselah","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101835_bib17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/apt.16945","article-title":"Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a \u2018real world\u2019 study","volume":"56","author":"Jachs","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2026.101835_bib18","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1128\/JCM.43.5.2363-2369.2005","article-title":"Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients","volume":"43","author":"Le Gal","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jhepr.2026.101835_bib19","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101835_bib20","series-title":"Handbuch Alkohol: \u00d6sterreich Band 1: Statistiken und Berechnungsgrundlagen","year":"2023"},{"key":"10.1016\/j.jhepr.2026.101835_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A phase 3, randomized trial of bulevirtide in chronic hepatitis d","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101835_bib22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jhep.2022.03.004","article-title":"Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV\/HDV-associated compensated cirrhosis","volume":"77","author":"Schwarz","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101835_bib23","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jhep.2024.12.044","article-title":"Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis","volume":"82","author":"Degasperi","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101835_bib24","article-title":"Treating hepatitis D with bulevirtide - real-world experience from 114 patients","volume":"5","author":"Dietz-Fricke","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101835_bib25","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jhep.2024.05.001","article-title":"Bulevirtide monotherapy in patients with chronic HDV: efficacy and safety results through week 96 from a phase III randomized trial","volume":"81","author":"Wedemeyer","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101835_bib26","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jhep.2024.01.035","article-title":"Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies","volume":"80","author":"Allweiss","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101835_bib27","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/hep.31214","article-title":"Long-term study of hepatitis delta virus infection at secondary care centers: the impact of viremia on liver-related outcomes","volume":"72","author":"Kamal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101835_bib28","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jhep.2020.11.032","article-title":"New insights into HDV persistence: the role of interferon response and implications for upcoming novel therapies","volume":"74","author":"Zhang","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101835_bib29","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jhep.2022.05.023","article-title":"Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread","volume":"77","author":"Zhang","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101835_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101835_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Te Lancet Infect Dis"},{"key":"10.1016\/j.jhepr.2026.101835_bib32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhepr.2026.101835_bib33","article-title":"Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression","volume":"5","author":"Jachs","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101835_bib34","article-title":"P158 Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis delta and 96 weeks of posttreatment follow-up","volume":"74","author":"Wedemeyer","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.101835_bib35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","article-title":"Clinical states of cirrhosis and competing risks","volume":"68","author":"D'Amico","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101835_bib36","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jhep.2020.11.048","article-title":"The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis","volume":"74","author":"Arroyo","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101835_bib37","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jhep.2020.10.004","article-title":"Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality","volume":"74","author":"Costa","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101835_bib38","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1111\/liv.15365","article-title":"Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease","volume":"42","author":"Simbrunner","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101835_bib39","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.3748\/wjg.v27.i29.4831","article-title":"Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease","volume":"27","author":"Khoo","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101835_bib40","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3851\/IMP1864","article-title":"Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-alpha2b plus ribavirin","volume":"16","author":"Ueyama","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhepr.2026.101835_bib41","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.cgh.2022.11.033","article-title":"Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis","volume":"21","author":"Hofer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101835_bib42","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.3390\/cells11223531","article-title":"Treatment of chronic hepatitis D with bulevirtide-a fight against two foes-an update","volume":"11","author":"Ferenci","year":"2022","journal-title":"Cells"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:26:01Z","timestamp":1783632361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926001060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2589555926001060"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101835","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response-guided bulevirtide \u00b1 pegylated interferon alfa-2a: Long-term outcomes observed in the nationwide Austrian hepatitis D cohort study","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101835","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101835"}}